S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
NASDAQ:HBIO

Harvard Bioscience - HBIO Stock Forecast, Price & News

$3.40
-0.13 (-3.68%)
(As of 08/8/2022 05:12 PM ET)
Add
Compare
Today's Range
$3.38
$3.55
50-Day Range
$3.28
$4.32
52-Week Range
$3.25
$8.75
Volume
156,654 shs
Average Volume
222,159 shs
Market Capitalization
$140.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Harvard Bioscience MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
105.3% Upside
$7.00 Price Target
Short Interest
Healthy
1.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.28mentions of Harvard Bioscience in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$34,000 Bought Last Quarter
Proj. Earnings Growth
23.08%
From $0.26 to $0.32 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.90 out of 5 stars

Computer And Technology Sector

67th out of 833 stocks

Analytical Instruments Industry

5th out of 35 stocks

HBIO stock logo

About Harvard Bioscience (NASDAQ:HBIO) Stock

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. TheStreet cut Harvard Bioscience from a "c" rating to a "d+" rating in a research note on Monday, May 23rd. KeyCorp decreased their target price on shares of Harvard Bioscience from $10.00 to $7.00 and set an "overweight" rating for the company in a research report on Friday.

Harvard Bioscience Price Performance

Shares of NASDAQ:HBIO opened at $3.53 on Monday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.42 and a quick ratio of 1.16. Harvard Bioscience has a twelve month low of $3.25 and a twelve month high of $8.75. The firm has a 50-day moving average of $3.70 and a two-hundred day moving average of $4.81.

Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

HBIO Stock News Headlines

See More Headlines
Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

HBIO Company Calendar

Last Earnings
11/02/2021
Today
8/08/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:HBIO
CUSIP
41690610
Employees
475
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+105.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-290,000.00
Pretax Margin
-2.01%

Debt

Sales & Book Value

Annual Sales
$118.90 million
Cash Flow
$0.37 per share
Book Value
$2.04 per share

Miscellaneous

Free Float
39,056,000
Market Cap
$140.22 million
Optionable
Optionable
Beta
1.71














HBIO Stock - Frequently Asked Questions

Should I buy or sell Harvard Bioscience stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HBIO shares.
View HBIO analyst ratings
or view top-rated stocks.

What is Harvard Bioscience's stock price forecast for 2022?

1 equities research analysts have issued 1 year target prices for Harvard Bioscience's stock. Their HBIO stock forecasts range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 104.7% from the stock's current price.
View analysts price targets for HBIO
or view top-rated stocks among Wall Street analysts.

How has Harvard Bioscience's stock price performed in 2022?

Harvard Bioscience's stock was trading at $7.05 at the start of the year. Since then, HBIO stock has decreased by 51.5% and is now trading at $3.42.
View the best growth stocks for 2022 here
.

Are investors shorting Harvard Bioscience?

Harvard Bioscience saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 365,700 shares, a decrease of 21.2% from the June 30th total of 464,000 shares. Based on an average daily volume of 308,000 shares, the short-interest ratio is currently 1.2 days. Approximately 1.0% of the shares of the company are short sold.
View Harvard Bioscience's Short Interest
.

When is Harvard Bioscience's next earnings date?

Harvard Bioscience is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our HBIO earnings forecast
.

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) posted its quarterly earnings results on Tuesday, November, 2nd. The medical instruments supplier reported $0.06 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.06. The medical instruments supplier had revenue of $29.66 million for the quarter, compared to analysts' expectations of $28.10 million. Harvard Bioscience had a positive trailing twelve-month return on equity of 7.74% and a negative net margin of 3.03%. During the same quarter in the previous year, the firm earned $0.01 earnings per share.

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia Oyj (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

What is Harvard Bioscience's stock symbol?

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

Who are Harvard Bioscience's major shareholders?

Harvard Bioscience's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Royce & Associates LP (3.93%), AMH Equity Ltd (3.03%), Monarch Partners Asset Management LLC (1.94%), Assenagon Asset Management S.A. (0.11%), Triton Wealth Management PLLC (0.09%) and Bailard Inc. (0.07%). Insiders that own company stock include Alan I Edrick, Bertrand Loy, James W Green, James W Green, Katherine A Eade, Thomas W Loewald and Value Fund Lp Palogic.
View institutional ownership trends
.

How do I buy shares of Harvard Bioscience?

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harvard Bioscience's stock price today?

One share of HBIO stock can currently be purchased for approximately $3.42.

How much money does Harvard Bioscience make?

Harvard Bioscience (NASDAQ:HBIO) has a market capitalization of $141.04 million and generates $118.90 million in revenue each year. The medical instruments supplier earns $-290,000.00 in net income (profit) each year or ($0.09) on an earnings per share basis.

How many employees does Harvard Bioscience have?

Harvard Bioscience employs 475 workers across the globe.

How can I contact Harvard Bioscience?

Harvard Bioscience's mailing address is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. The official website for the company is www.harvardbioscience.com. The medical instruments supplier can be reached via phone at (508) 893-8999, via email at info@harvardbioscience.com, or via fax at 508-429-5732.

This page (NASDAQ:HBIO) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.